Dr. Paul B. Chapman

Dr. Paul B. Chapman, MD, is a highly regarded medical oncologist specializing in the diagnosis and treatment of melanoma and other skin cancers. He serves as an attending physician on the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center and holds an academic appointment as Professor of Medicine at Weill Cornell Medical College. Dr. Chapman earned his medical degree from Cornell University Medical College, completed his residency in internal medicine at NewYork-Presbyterian/Weill Cornell, and pursued fellowship training in medical oncology at Memorial Sloan Kettering, where he has spent the majority of his distinguished career advancing cancer care and research.

Dr. Chapman is known for his pioneering work in the development of targeted therapies for advanced melanoma, particularly his contributions to clinical trials involving BRAF inhibitors and other precision-based treatments. His research has significantly shaped the standard of care for metastatic melanoma, with a focus on drug resistance mechanisms, biomarker development, and novel therapeutic combinations. He has authored numerous peer-reviewed studies and remains active in national and international research initiatives dedicated to skin cancer therapeutics.

Beyond his scientific and clinical contributions, Dr. Chapman is a dedicated mentor and educator, guiding oncology trainees and junior investigators through Memorial Sloan Kettering’s academic and research programs. He is known for his collaborative, patient-focused approach to care and his leadership in fostering multidisciplinary innovation in oncology. Through his commitment to translational research, clinical excellence, and medical education, Dr. Chapman continues to play a central role in advancing the treatment and understanding of melanoma.